PDF(Pubmed)
Abstract：
UNASSIGNED: Rotavirus and Hepatitis A virus are responsible for causing gastroenteritis and jaundice. The current vaccination approaches have proven insufficient, especially in low-income countries. In this study, we presented a novel dual-vaccine candidate that combines the rotavirus VP8 protein and the hepatitis A virus VP1.
UNASSIGNED: The VP8*-rotavirus+AAY+HAV-VP1 fusion protein was produced using an Escherichia coli expression system. The recombinant protein had a molecular weight of approximately 45.5 kDa and was purified through affinity chromatography. BALB/c mice were injected subcutaneously with the recombinant protein, VP1, VP8 and vaccines for rotavirus and hepatitis A virus, both with and without ALUM and M720 adjuvants. ELISA assays were used to measure total IgG, IgG1, IgG2, and short-term and long-term IL-5 and IFN-γ responses.
UNASSIGNED: The fusion protein, when combined with adjuvants, elicited significantly higher total IgG, IgG1, and IgG2 responses compared to VP1 and VP8 alone, as well as the rotavirus and hepatitis A vaccines. Furthermore, it induced a higher short-term IL-5 and IFN-γ response while demonstrating a higher long-term IL-5 response compared to the rotavirus and hepatitis A vaccines.
UNASSIGNED: This study demonstrates that the VP8*-rotavirus+AAY+HAV-VP1 fusion protein is a promising dual vaccine candidate for immunization against hepatitis A and rotaviruses.
UNASSIGNED: The VP8*-rotavirus+AAY+HAV-VP1 fusion protein was produced using an Escherichia coli expression system. The recombinant protein had a molecular weight of approximately 45.5 kDa and was purified through affinity chromatography. BALB/c mice were injected subcutaneously with the recombinant protein, VP1, VP8 and vaccines for rotavirus and hepatitis A virus, both with and without ALUM and M720 adjuvants. ELISA assays were used to measure total IgG, IgG1, IgG2, and short-term and long-term IL-5 and IFN-γ responses.
UNASSIGNED: The fusion protein, when combined with adjuvants, elicited significantly higher total IgG, IgG1, and IgG2 responses compared to VP1 and VP8 alone, as well as the rotavirus and hepatitis A vaccines. Furthermore, it induced a higher short-term IL-5 and IFN-γ response while demonstrating a higher long-term IL-5 response compared to the rotavirus and hepatitis A vaccines.
UNASSIGNED: This study demonstrates that the VP8*-rotavirus+AAY+HAV-VP1 fusion protein is a promising dual vaccine candidate for immunization against hepatitis A and rotaviruses.
摘要：
轮状病毒和甲型肝炎病毒是引起胃肠炎和黄疸的原因。目前的疫苗接种方法已被证明是不够的，特别是在低收入国家。在这项研究中,我们提出了一种新的联合轮状病毒VP8蛋白和甲型肝炎病毒VP1的双重候选疫苗.
■使用大肠杆菌表达系统产生VP8*-轮状病毒+AAY+HAV-VP1融合蛋白。重组蛋白的分子量约为45.5kDa,通过亲和层析纯化。BALB/c小鼠皮下注射重组蛋白,VP1，VP8和轮状病毒和甲型肝炎病毒疫苗，有和没有ALUM和M720佐剂。ELISA测定用于测量总IgG，IgG1、IgG2以及短期和长期IL-5和IFN-γ应答。
■融合蛋白，当与佐剂结合使用时，引起明显更高的总IgG，与单独的VP1和VP8相比，IgG1和IgG2应答，以及轮状病毒和甲型肝炎疫苗。此外，与轮状病毒和甲型肝炎疫苗相比，它诱导了更高的短期IL-5和IFN-γ反应，同时表现出更高的长期IL-5反应。
■这项研究表明，VP8*-轮状病毒+AAY+HAV-VP1融合蛋白是免疫甲型肝炎和轮状病毒的有希望的双重疫苗候选物。
■使用大肠杆菌表达系统产生VP8*-轮状病毒+AAY+HAV-VP1融合蛋白。重组蛋白的分子量约为45.5kDa,通过亲和层析纯化。BALB/c小鼠皮下注射重组蛋白,VP1，VP8和轮状病毒和甲型肝炎病毒疫苗，有和没有ALUM和M720佐剂。ELISA测定用于测量总IgG，IgG1、IgG2以及短期和长期IL-5和IFN-γ应答。
■融合蛋白，当与佐剂结合使用时，引起明显更高的总IgG，与单独的VP1和VP8相比，IgG1和IgG2应答，以及轮状病毒和甲型肝炎疫苗。此外，与轮状病毒和甲型肝炎疫苗相比，它诱导了更高的短期IL-5和IFN-γ反应，同时表现出更高的长期IL-5反应。
■这项研究表明，VP8*-轮状病毒+AAY+HAV-VP1融合蛋白是免疫甲型肝炎和轮状病毒的有希望的双重疫苗候选物。
